These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 37427373)

  • 1. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy.
    Li M; Sun J; Shi G
    Front Cell Dev Biol; 2023; 11():1220376. PubMed ID: 37427373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
    Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
    Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR screen in cancer: status quo and future perspectives.
    He C; Han S; Chang Y; Wu M; Zhao Y; Chen C; Chu X
    Am J Cancer Res; 2021; 11(4):1031-1050. PubMed ID: 33948344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
    Yim S; Hwang W; Han N; Lee D
    Front Immunol; 2022; 13():884561. PubMed ID: 35651625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
    Ou X; Ma Q; Yin W; Ma X; He Z
    Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
    Xu Y; Chen C; Guo Y; Hu S; Sun Z
    Front Immunol; 2022; 13():848327. PubMed ID: 35300341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.
    Elmas E; Saljoughian N; de Souza Fernandes Pereira M; Tullius BP; Sorathia K; Nakkula RJ; Lee DA; Naeimi Kararoudi M
    Front Oncol; 2022; 12():834002. PubMed ID: 35449580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
    Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
    Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
    Wang L; Chen Y; Liu X; Li Z; Dai X
    Front Oncol; 2021; 11():704999. PubMed ID: 35111663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Cancer Immunotherapy with CRISPR-Based Technology.
    Li Z; Fei T
    Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The applications of CRISPR screen in functional genomics.
    Qi X; Zhang J; Zhao Y; Chen T; Xiang Y; Hui J; Cai D; Liu Y; Xia L; Yu T; Li G
    Brief Funct Genomics; 2017 Jan; 16(1):34-37. PubMed ID: 27329784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
    Jiang C; Meng L; Yang B; Luo X
    Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer.
    Maity S; Mukherjee R; Banerjee S
    Mol Biotechnol; 2023 Feb; 65(2):206-226. PubMed ID: 35999480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research.
    Yang Y; Xu J; Ge S; Lai L
    Front Med (Lausanne); 2021; 8():649896. PubMed ID: 33748164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.